Many patients struggle to maintain glycemic control, especially when they have busy lifestyles – work, family, friends, volunteering, exercise – all factors contribute to glycemic goals and diabetes treatment plans. Good glycemic control can help your patients avoid future complications and have a better quality of life. Eversense XL helps patients maintain that control while having one less thing to think about, since it’s always there for your patients. With 288 readings per day and up to 180 days of sensor life, Eversense XL can give your patients the freedom that they’ve been searching for.
Not just better health, a better quality of life.
Having diabetes is hard enough. Eversense wants to help make it easier for your patients to manage. As part of our European clinical trial, we asked users how Eversense impacted their life.2
- 85% had increased confidence over their diabetes control
- 90% said it made living with diabetes less of a burden
- 76% felt more confident about avoiding severe hypoglycemia
- 88% said it helped them deal more easily with their diabetes
- 72% felt safer when sleeping
Patient Feedback on Eversense XL
OVERWHELMING MAJORITY OF EVERSENSE USERS FEEL OPTIMISTIC AND SAFE
A lifestyle friendly design that improves wear time and confidence.
- Enhanced psychosocial outcomes are linked to duration of CGM use.3,4
The first and only long-term CGM system that lasts up to 180 days.
Implantable sensor eliminates self-insertions and site maintenance.
Silicone-based, hypoallergenic adhesive has shown no irritation or reactions.5*
Sign Up Your Patients Today!
Fill out the form and we'll have a representative contact you.Click Here
1 De Bock M, Cooper M, Retterath A, et al. Continuous Glucose Monitoring Adherence: Lessons From a Clinical Trial to Predict Outpatient Behavior. Journal of Diabetes Science and Technology. 2016;10(3): 627-632.doi:10.1177/1932296816633484. 2 Beck RW, MD, Hirsch IB, La_el L, Tamborlane WV, et al. E_ect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009 August; 32(8): 1378–1383. 3 Tansey M. Diabetic Medicine, Volume28, Issue9, September 2011, Pages 1118-1122. 4 Kubiak T. Journal of Diabetes Science and Technology. 2016, Vol. 10(4) 859–863. 5 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
MKT-001282 Rev 2